Skip to main content
. 2016 Nov 7;126(12):4585–4602. doi: 10.1172/JCI86505

Figure 9. miR-424 inhibition disrupts the miR-424/COP1/STAT3 axis in vivo.

Figure 9

(A) Schematic of the experimental plan. (B) Tumor incidence in control-treated (Scr n = 10) and anti–miR-424–treated (Anti-424 n = 9) DU145 cells. Significance was calculated by Fisher exact test. Two-tailed P = 0.023. (C and D) Tumor growth monitored by tumor size (C) and in vivo bioluminescence (D) of subcutaneous xenografts (mean ± SEM, Scr n = 6 and Anti-424 n = 2) of DU145-Luc cells pretreated in vitro with anti–miR-424 or Scr. (E) Ex vivo SFE from Scr or Anti-424 dissociated tumor xenografts. (F) IHC staining for STAT3, p-STAT3, COP1, and Ki67 in tumor xenografts of DU145 cells treated with Anti-424 or Scr. Scale bars: 10 μm. (G) qRT-PCR evaluation of selected STAT3 targets (top) and selected cancer stem cell markers (bottom) in tumor xenografts from control (Scr) and miR-424–ablated (Anti-424) xenografts. (H) Schematic of the experimental plan. (I) Lung metastasis from DU145-Luc cells pretreated in vitro with Anti-424 or Scr and injected into the tail vein of nude mice. Representative bioluminescent images (left); quantification after necropsy of lung metastatic foci (right). (J) Representative images of H&E, immunostaining, and IHC scores (percentage of positive cells). Areas within the boxes in top panels are magnified in the lower samples. Scale bars: 100 μm. *P < 0.05; **P < 0.01.